Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 27, Issue 1, Pages 1-8Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2017.1262350
Keywords
Retinoid-related orphan receptor gamma t; ROR gamma t; RORc2; VTP-43742; VTP-45489; back-up compound
Categories
Ask authors/readers for more resources
Retinoic acid receptor-related orphan nuclear receptor gamma t (ROR gamma t or RORc2) is a key transcription factor for the differentiation of naive proinflammatory CD4(+) T cells and the production of T helper-17 (T(H)17) cells. Inhibiting ROR gamma t activity is thought to be beneficial in targeting a variety of inflammatory and autoimmune disorders. Recently Vitae Pharmaceuticals (to be acquired by Allergan) reported positive top-line results from a Phase 2a clinical trial of ROR gamma t inhibitor VTP-43742 in psoriatic patients. The compound was reported to demonstrate a clear signal of efficacy over a short four-week period and no drug-related cardiac abnormalities were observed; however, in the 700mg dose group reversible transaminase elevations were observed in four patients, which prompted the company to cancel testing VTP-43742 at a initially planned third, higher dose. In Vitae Pharmaceuticals latest patent applications, WO2016061160 and US20160122345, potential dihydropyrrolopyridine back-up compounds of clinical candidate VTP-43742 (covered in WO2015116904) are disclosed. In light of the recently announced ROR gamma t back-up molecule VTP-45489, the improvements of the new compounds are discussed and their potential impact is elucidated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available